[Captopril in single doses in the treatment mild-moderated arterial hypertension]. 1990

J Alcántara Nicolás, and R Cano Cano, and E Cano Cano, and C Contreras, and J A García Galvis, and L García Giralda, and J González Comeche, and A Madrid Conesa, and F Ramos La Torre, and J Sánchez Moreno
GRAMU, Unidad de Hipertensión Hospitalaria, Murcia.

The effect of single dose (50 mg) Captopril (C) used either alone or associated to diuretics (50 mg hydrochlorothiazide -HCTI) in the treatment of mild-moderate essential arterial hypertension was studied in a multicentric study. Eighty eight patients were chosen. After a minimum of 4 month follow-up period 53.4% responded (BDP less than 95 mm Hg) to single dose C (group 1:47 patients), 89.77% to 50 mg C in single dose together with 50 mg HTIT (group 2: 32 patients), 95.45% of two 50 mg doses of C and 50 mg HCIT (group 3: 5 patients), and 97.72% responded to 3 doses of C and 50 mg of HCTI (group 4: 2 patients). The decrease in blood pressure values was statistically significant (p, 000, Wilcoxon test) in groups 1 and 2, having a mean decrease in blood pressure (BP) of 14%. In group 1 (n = 42) the SBP which initially was 165.72 +/- 11.32, decreased to 148.28 +/- 11.5 and the DBP decreased from 101.55 +/- 5.68 to 87.28 +/- 6.59. In group 2 (n = 32) the SBP decreased from 173.50 +/- 14.08 to 152.44 +/- 20.8 and the DBP from 103.34 +/- 5.29 to 87.47 +/- 6.39. The response to monotherapy could not be statistically correlated either to early essential hypertension or to the patients age. Treatment was discontinued in three cases due to the secondary effects, cough, ageusia and nervousness, showing the remaining patients a good tolerance. No changes were observed in the analytical parameters. This study shows the usefulness and tolerance of single dose C as the initial treatment of mild to moderate essential hypertension.

UI MeSH Term Description Entries
D006973 Hypertension Persistently high systemic arterial BLOOD PRESSURE. Based on multiple readings (BLOOD PRESSURE DETERMINATION), hypertension is currently defined as when SYSTOLIC PRESSURE is consistently greater than 140 mm Hg or when DIASTOLIC PRESSURE is consistently 90 mm Hg or more. Blood Pressure, High,Blood Pressures, High,High Blood Pressure,High Blood Pressures
D008875 Middle Aged An adult aged 45 - 64 years. Middle Age
D002216 Captopril A potent and specific inhibitor of PEPTIDYL-DIPEPTIDASE A. It blocks the conversion of ANGIOTENSIN I to ANGIOTENSIN II, a vasoconstrictor and important regulator of arterial blood pressure. Captopril acts to suppress the RENIN-ANGIOTENSIN SYSTEM and inhibits pressure responses to exogenous angiotensin. (S)-1-(3-Mercapto-2-methyl-1-oxopropyl)-L-proline,Capoten,Lopirin,SQ-14,225,SQ-14,534,SQ-14225,SQ-14534,SQ 14,225,SQ 14,534,SQ 14225,SQ 14534,SQ14,225,SQ14,534,SQ14225,SQ14534
D002985 Clinical Protocols Precise and detailed plans for the study of a medical or biomedical problem and/or plans for a regimen of therapy. Protocols, Clinical,Research Protocols, Clinical,Treatment Protocols,Clinical Protocol,Clinical Research Protocol,Clinical Research Protocols,Protocol, Clinical,Protocol, Clinical Research,Protocols, Clinical Research,Protocols, Treatment,Research Protocol, Clinical,Treatment Protocol
D003971 Diastole Post-systolic relaxation of the HEART, especially the HEART VENTRICLES. Diastoles
D004341 Drug Evaluation Any process by which toxicity, metabolism, absorption, elimination, preferred route of administration, safe dosage range, etc., for a drug or group of drugs is determined through clinical assessment in humans or veterinary animals. Evaluation Studies, Drug,Drug Evaluation Studies,Drug Evaluation Study,Drug Evaluations,Evaluation Study, Drug,Evaluation, Drug,Evaluations, Drug,Studies, Drug Evaluation,Study, Drug Evaluation
D004359 Drug Therapy, Combination Therapy with two or more separate preparations given for a combined effect. Combination Chemotherapy,Polychemotherapy,Chemotherapy, Combination,Combination Drug Therapy,Drug Polytherapy,Therapy, Combination Drug,Chemotherapies, Combination,Combination Chemotherapies,Combination Drug Therapies,Drug Polytherapies,Drug Therapies, Combination,Polychemotherapies,Polytherapies, Drug,Polytherapy, Drug,Therapies, Combination Drug
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D006852 Hydrochlorothiazide A thiazide diuretic often considered the prototypical member of this class. It reduces the reabsorption of electrolytes from the renal tubules. This results in increased excretion of water and electrolytes, including sodium, potassium, chloride, and magnesium. It is used in the treatment of several disorders including edema, hypertension, diabetes insipidus, and hypoparathyroidism. Dichlothiazide,Dihydrochlorothiazide,Esidrex,Esidrix,HCTZ,HydroDIURIL,Hypothiazide,Oretic,Sectrazide
D000328 Adult A person having attained full growth or maturity. Adults are of 19 through 44 years of age. For a person between 19 and 24 years of age, YOUNG ADULT is available. Adults

Related Publications

J Alcántara Nicolás, and R Cano Cano, and E Cano Cano, and C Contreras, and J A García Galvis, and L García Giralda, and J González Comeche, and A Madrid Conesa, and F Ramos La Torre, and J Sánchez Moreno
May 1984, Arquivos brasileiros de cardiologia,
J Alcántara Nicolás, and R Cano Cano, and E Cano Cano, and C Contreras, and J A García Galvis, and L García Giralda, and J González Comeche, and A Madrid Conesa, and F Ramos La Torre, and J Sánchez Moreno
June 1980, AMB : revista da Associacao Medica Brasileira,
J Alcántara Nicolás, and R Cano Cano, and E Cano Cano, and C Contreras, and J A García Galvis, and L García Giralda, and J González Comeche, and A Madrid Conesa, and F Ramos La Torre, and J Sánchez Moreno
June 1984, Arquivos brasileiros de cardiologia,
J Alcántara Nicolás, and R Cano Cano, and E Cano Cano, and C Contreras, and J A García Galvis, and L García Giralda, and J González Comeche, and A Madrid Conesa, and F Ramos La Torre, and J Sánchez Moreno
February 1992, Anales de medicina interna (Madrid, Spain : 1984),
J Alcántara Nicolás, and R Cano Cano, and E Cano Cano, and C Contreras, and J A García Galvis, and L García Giralda, and J González Comeche, and A Madrid Conesa, and F Ramos La Torre, and J Sánchez Moreno
January 1987, Terapevticheskii arkhiv,
J Alcántara Nicolás, and R Cano Cano, and E Cano Cano, and C Contreras, and J A García Galvis, and L García Giralda, and J González Comeche, and A Madrid Conesa, and F Ramos La Torre, and J Sánchez Moreno
January 1982, British journal of clinical pharmacology,
J Alcántara Nicolás, and R Cano Cano, and E Cano Cano, and C Contreras, and J A García Galvis, and L García Giralda, and J González Comeche, and A Madrid Conesa, and F Ramos La Torre, and J Sánchez Moreno
January 1982, Minerva cardioangiologica,
J Alcántara Nicolás, and R Cano Cano, and E Cano Cano, and C Contreras, and J A García Galvis, and L García Giralda, and J González Comeche, and A Madrid Conesa, and F Ramos La Torre, and J Sánchez Moreno
August 1984, Arquivos brasileiros de cardiologia,
J Alcántara Nicolás, and R Cano Cano, and E Cano Cano, and C Contreras, and J A García Galvis, and L García Giralda, and J González Comeche, and A Madrid Conesa, and F Ramos La Torre, and J Sánchez Moreno
March 1990, Anales espanoles de pediatria,
J Alcántara Nicolás, and R Cano Cano, and E Cano Cano, and C Contreras, and J A García Galvis, and L García Giralda, and J González Comeche, and A Madrid Conesa, and F Ramos La Torre, and J Sánchez Moreno
September 1980, La Nouvelle presse medicale,
Copied contents to your clipboard!